Last reviewed · How we verify
UB-421 SC
At a glance
| Generic name | UB-421 SC |
|---|---|
| Also known as | Humanized dB4C7C22-6 monoclonal antibody |
| Sponsor | United BioPharma |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients (PHASE1)
- Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UB-421 SC CI brief — competitive landscape report
- UB-421 SC updates RSS · CI watch RSS
- United BioPharma portfolio CI